Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUBLIVAC FIX Phleum pratense dose-finding study in grass pollen allergic rhinitis/rhinoconjunctivitis
2010-021235-13Phase 2Completed
- Sponsor
- HAL Allergy Group
- Start
- May 2012
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of phleum pratense extract in allergic rhinitis (AR) and allergic rhinoconjunctivitis (ARC) (5 arms), sponsored by HAL Allergy Group. Primary endpoint: Absolute difference in mean total symptom score in the TNPT. Started May 2012; status: completed.
02
Drugs
phleum pratense extract
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2010-021235-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021235-13.